MilliporeSigma
  • Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.

Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease.

Pediatrics (2013-11-28)
Ran D Goldman, William Mounstephen, Melanie Kirby-Allen, Jeremy N Friedman
ABSTRACT

Vaso-occlusive episodes (VOEs) are the most common complication of sickle cell disease in children. Treatment with magnesium seems to improve cellular hydration and may result in reduced vaso-occlusion. This study aimed to determine if intravenous (IV) magnesium sulfate (MgSO4) reduces length of stay (LOS) in hospital, pain scores, and cumulative analgesia when compared with placebo. Randomized, double-blind, placebo-controlled trial in children aged 4 to 18 years requiring admission to hospital with a sickle cell disease VOE requiring IV analgesia. Participating children received IV MgSO4 (100 mg/kg) every 8 hours or placebo in addition to standard therapy. We used a t test or Mann-Whitney test (continuous variables), Fisher's exact test, or χ2 test (frequencies). P values were considered significant if <.05, and 95% confidence intervals were calculated for the difference between groups. One hundred six children were randomly assigned to the study, and 104 were included. Fifty-one (49%) received MgSO4. Children's mean age was 12.4 years (range: 4-18 years; SD: 3.8 years), and 56 (54%) were females. There was no significant difference in the primary outcome measure, LOS in hospital, with a mean of 132.6 and 117.7 hours in the MgSO4 and placebo groups, respectively (P = .41). There was no significant difference between groups for the secondary outcomes of mean pain scores (4.9 ± 2.6 vs 4.8 ± 2.6, respectively; P = .92) or analgesic requirements (continuous morphine infusion [P = .928], boluses of IV morphine [P = .82], acetaminophen [P = .34], ibuprofen [P = .15], naproxen [P = .10]). Only minor adverse events were recorded in both groups. Pain at the infusion site was more common in the MgSO4 group. IV MgSO4 was well tolerated but had no effect on the LOS in hospital, pain scores, or cumulative analgesia use in admitted children with a VOE.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Magnesium sulfate heptahydrate, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesium sulfate heptahydrate, BioReagent, for molecular biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Magnesium sulfate heptahydrate, BioXtra, ≥99.0%
Sigma-Aldrich
Magnesium sulfate heptahydrate, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Magnesium sulfate heptahydrate, puriss. p.a., ACS reagent, ≥99.0% (KT)
Sigma-Aldrich
Magnesium sulfate heptahydrate, ACS reagent, ≥98%
Sigma-Aldrich
Magnesium sulfate heptahydrate, 99.5-100.5% (calc. to the dried substance), meets analytical specification of Ph. Eur., BP,USP, FCC
Sigma-Aldrich
Magnesium sulfate, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Magnesium sulfate, anhydrous, reagent grade, ≥97%
Sigma-Aldrich
Magnesium sulfate, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Magnesium sulfate, ≥99.99% trace metals basis
Sigma-Aldrich
Magnesium sulfate solution, for molecular biology, 1.00 M±0.04 M
Sigma-Aldrich
Magnesium sulfate, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Magnesium sulfate solution, BioUltra, for molecular biology